An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/19023496

Download in:

View as

General Info

PMID
19023496